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854Dendritic Cell Count in the Graft Predicts Relapse in
Patients with Hematologic Malignancies Undergoing an
HLA-Matched Related Allogeneic Peripheral Blood
Stem Cell Transplant
Reena Rajasekar, Kavitha M. Lakshmi, Biju George, Auro Viswabandya,
Rajasekar Thirugnanam, Aby Abraham, Mammen Chandy, Alok Srivastava, VikramMathewsWe investigated the impact of the number of infused and reconstituted immunocompetent cells including
dendritic cells (DCs) on clinical outcome of patients with hematologic malignancies undergoing an allogeneic
peripheral blood stem cell transplantation. Sixty-nine consecutive patients with hematologic malignancies
were included in the analysis. The median age of the cohort was 32 years (range: 2-62 years) and there
were 39 (57%)males. Twenty-one (30%) patients relapsedwith a cumulative incidence of 44 %6 14% at ame-
dian follow up of 28 months. On a multivariate analysis, a high plasmacytoid dendritic cell (PC) content in the
graft was associated with higher risk of relapse. The patients were further categorized based on the median
PC counts in the graft as high ($2.3 106/kg) and low (\2.3  106/kg) groups. The baseline characteristics
of these 2 groups were comparable. The group that had a high PC content in the graft had significantly higher
risk of relapse and lower overall survival (OS) and event-free survival (EFS). Our data suggests that PC con-
tent in the graft predicts clinical outcomes such as relapse and survival in patients with hematologic malig-
nancies undergoing an allogeneic HLA matched related peripheral blood stem cell transplantation. There
is potential for pretransplant manipulation of this cellular subset in the graft.
Biol Blood Marrow Transplant 16: 854-860 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Dendritic cells, Graft composition, Immune reconstitution, Relapse riskINTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(SCT) remains the best therapeutic option for a num-
ber of malignant hematologic diseases. Significant
obstacles limiting the efficacy of SCT are the occur-
rence of regimen-related toxicity, graft-versus-host
disease (GVHD), relapse, engraftment failure, and
susceptibility of patients to opportunistic infections
after transplantation [1-3]. Relapse of the underlying
hematologic malignancy remains the most frequent
cause of treatment failure. There are limited
nonmalignancy-related parameters that can robustly
predict relapse after amatched related allogeneic SCT.Department of Haematology, Christian Medical College,
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6/j.bbmt.2010.01.013After SCT, an immune response is determined early
by both mature immunocompetent cells transferred
within the allograft and by immune cells that develop
de novo from transplanted stem cells. Different cell
lineages reconstitute at different rates, and this could
have an impact on clinical outcomes posttransplantation
[4,5]. In addition to stem cells, the graft also contains
other immunocompetent cells. Besides the effect of the
T cell dose in the graft, there is limited understanding
of the impact of other small cellular subsets on clinical
outcomes posttransplantation.
Dendritic cells (DCs) are professional antigen-
presenting cells (APCs) involved in induction and reg-
ulation of immune responses. DC precursors in blood
constitute\1% ofmononuclear cells [6]. According to
their potential ability to induce naı¨ve T cell differenti-
ation to Th1 and Th2 effector cells, 2 distinct lineages
of DCs have been identified, namely, monocytoid
(MC) and plasmacytoid (PC) DCs, which do not ex-
press lineage markers (CD3, CD14, CD16, CD19,
CD20, and CD56), but are positive for HLA-DR
and either CD11c or CD123 (IL-3 receptor a-chain),
respectively [7,8]. Despite a 10-fold higher dose of
transplanted T cells in peripheral blood stem cell
(PBSC) recipients compared to bone marrow (BM)
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in a significantly higher proportion among PBSC
recipients as one would have anticipated based on the
T cell dose. It has been hypothesized that this is
attributable to granulocyte-colony stimulating factor
(G-CSF) selectively mobilizing PC DCs and the abil-
ity of activated PC DCs to prime T lymphocytes to
produce Th2 cytokines that favor immunotolerance
[9,10].
Anumber of reports have suggested that the pattern
and rate of recovery of different subsets can predict the
clinical outcome. An early low plasmacytoid DC count
has been reported by us and others to be associatedwith
aGVHD and chronic GVHD (cGVHD) [11,12].
However, there is limited understanding of the
impact of DC dose in the graft on clinical outcomes.
It was assumed because of their low numbers in the
graft, limited potential for survival postinfusion, and
the significantly larger number of recipient DC that
survive the conditioning regimen that they were
unlikely to have a significant impact on clinical
outcomes [13]. Prior to the clear definition of what
constituted the immunophenotype of a plasmacytoid
DC, Waller et al. [14] had reported a high incidence
of relapse associated with large cell dose of CD4bright
DC. Recently, Taylor et al. [15] have shown an impor-
tant effect of donor APCs, contained in the graft, in
activating host immunity and effector T cells that
mediate graft rejection.We hypothesized that immune
cells, particularly DCs, both in the graft and those
engrafted posttransplant, would have an important
impact on relapse and survival given the central role
of these cells in the immune response.
As part of a prospective immune reconstitution
study, data was collected on various cellular subsets
in the graft and in the post transplant period. This
data set was analyzed for the impact of DC content
in the graft on clinical outcomes among patients with
a hematologic malignancy under going an allogeneic
PBSC transplantation (PBSCT).PATIENTS, MATERIALS, AND METHODS
All patients with a hematologic malignancy who
underwent an allogeneic HLA matched related
G-CSF mobilized PBSCT at our center, between
March 2005 and February 2007, were included in
this immune-reconstitution study. A written informed
consent was obtained from all patients, and in the case
of minors, from their parents or legal guardians. Pa-
tients were nursed in rooms with a positive-pressure
HEPA-filtered air.
Conditioning
Conditioning regimenusedwas either amyeloabla-
tive (MA) or a reduced-intensity regimen.Ma regimenswere either oral busulfan (16 mg/kg) and cyclophos-
phamide (120 mg/kg) or cyclophosphamide (120 mg/
kg) with total body irradiation (TBI) (1200 cGy in 6 sit-
tings over 3 days). Reduced-intensity conditioning reg-
imen in the majority was fludarabine based (Table 1).Graft Source and Engraftment
G-CSF-stimulated PBSCs were collected from the
donor with a target cell dose of 5 106 CD34/kg body
weight of the recipient. Neutrophil engraftment was
defined as the first of 3 consecutive days with absolute
neutrophil count (ANC).0.5 109/Lt,whereas plate-
let engraftment was defined as the first of 3 consecutive
untransfused platelet counts .20  109/Lt. Samples
were obtained fromPBSCgrafts and from the PBof re-
cipients in the posttransplant period on day 15, day 28,
day 45, 2 months, 3 months, 6 months, 9 months, and
12 months for flow cytometry analysis. Chimerism
analysis using variable number tandem repeats
(VNTR) was done at day 30 post-PBSCT.GVHD Prophylaxis
Cyclosporine (CsA) and short-coursemethotrexate
was used as GVHD prophylaxis in the majority of pa-
tients. CsA was administered at a dose of 2.5 mg/kg in-
travenously over 4 hours twice daily starting on day24,
and changed to oral route at 5 mg/kg twice daily when
mucositis had resolved. CsA levels weremonitored and
the dose adjusted to achieve a target level of 200-400
ng/mL. The methotrexate dose was 10 mg/m2 on day
1 and 7 mg/m2 on days 3, 6, and 11 (in 16 cases the
day 1 dose was 15mg/m2 and the day 3, 6, and 11 doses
were 10 mg/m2). If mucositis was severe (grade III/IV)
or bilirubin.20mg/L, the day 6 and day 11 doses were
omitted. aGVHD was treated with dexamethasone or
methyl prednisone. Steroid refractory GVHD was
treated as per the discretion of the treating physician.
Patients who died before day 28 were excluded from
DC analysis.Definition of Outcomes
Relapse was defined on the basis of morphologic
evidence of leukemia in BM, or other extramedullary
organs. Event-free survival (EFS) was calculated from
time of initiating conditioning regimen to last follow-
up or an event (relapse or death). Overall survival (OS)
was defined as time from initiating conditioning
regimen to last follow-up or death because of any cause.
High-risk diseases were defined as acute myelogenous
leukemia (AML) beyond first complete remission
(CR), acute lymphoblastic leukemia (ALL) excluding
those that were Philadelphia chromosome positive,
Philadelphia chromosome positive ALL beyond
$CR2, myelodysplastic syndrome (excluding MDS-
RA), myelofibrosis, advanced phase chronic
Table 1. Patient Characteristics and Details of Peripheral
Blood Stem Cell Transplants
Characteristics n (%)/median (range)
Patients
Males 39 (57)
Age (years) 32 (2-62)
Donors —
Males 40 (58)
Age (years) 34 (11-63)
Diagnosis —
Acute myelogenous leukemia 41 (59)
Acute lymphoblastic leukemia 10 (15)
Chronic myelogenous leukaemia 8 (11)
Myelodysplastic syndrome 6 (9)
Biphenotypic acute leukemia 3 (4)
Myelofibrosis 1 (1)
Conditioning regimen
Myeloablative 37 (54)
Bu/Cy 19 (28)
Cy/TBI 18 (26)
Reduced intensity 32 (46)
Flu/Mel 21 (30)
Flu/Cy 3 (4)
Flu/Cy/ATG 1 (1)
Ida/Flu/cytosine 7 (10)
GVHD prophylaxis
CsA 4 (6)
CsA+ MTX 63 (92)
CsA+ Methylprednisolone 1(1)
Mycophenolate 1(1)
ATGindicates antithymocyte globulin; Bu, busulfan;Cy, cyclophosphamide;
Flu, fludarabine; Mel, melphalan; TBI, total body irradiation; CsA,
cyclosporine; MTX, methotrexate.
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multiply relapsed malignancies.Flow Cytometric Analysis
Harvest samples from donors and PB samples from
posttransplant patients were assessed for stem cells,
lymphocyte subsets, and DCs subsets. Briefly, cells
were labeled using a panel of monoclonal antibodies
to CD34 (stem cells), CD133 (stem cells), CD3 (T
cells), CD4 (Helper T), CD45RA(naı¨ve), CD45RO
(memory), CD8 (cytotoxic), CD19 (B cells), CD56,
andCD16 (natural killer [NK]cells) directly conjugated
eitherwithfluorescein isothiocyanate (FITC),phycoer-
ythrin (PE) or peridinin chlorophyll protein (PerCP)
(Becton Dickinson, San Jose, CA, USA) followed by
red cell lysis with ammonium chloride. DCs were char-
acterized as monocytoid (Lin2, HLA-DR1, CD11c1)
and plasmacytoid (Lin2, HLA-DR1, CD1231) DCs
(antibodies toCD11c andCD123 fromBectonDickin-
son). The cells were then washed and analyzed using
FACSCalibur (Becton Dickenson, Mansfield, MA,
USA).Data analysiswasperformedusingCellQuestPro
software (Becton Dickenson, Mansfield, MA, USA).
Lymphocyte subset percentages were calculated from
the lymphocyte gate as appropriate. The absolute lym-
phocyte subset counts were then calculated from rou-
tine leukocyte differential counts. For stem cell
enumeration (CD34) in the graft, ISHAGE gatingstrategy was performed as described previously [16].
Previously describedmethod for identification andenu-
merationofDCsubsetswas used [17].Cells negative for
lineage markers (Lin2) were gated and then analyzed
for HLA-DR and CD11c for MC and CD123 expres-
sion for PC.
Statistical Analysis
Chi-square and Mann-Whitney U-tests were used
for parametric and nonparametric data, respectively.
The probability of survival was estimated using the
Kaplan-Meier method for relapse, GVHD, day 100
treatment-related mortality, EFS, and OS. Log-rank
tests were used to measure significant differences be-
tween strata. Cox models were used to assess the pro-
portional hazards of various subsets both in the graft
and those engrafted after transplant for outcomes in
relation to the clinically related variables including re-
cipient/donor age, sex, sex mismatch (in particular, fe-
male donor to male recipient), conditioning regimen,
and cell doses administered at the time of transplant.
To confirm outcomes and to adjust for potential con-
founding factors, multivariate Cox proportional haz-
ards models were also performed. Patients who died
before engraftment or had a disease relapse after trans-
plantation were censored at those time points for
immune reconstitution studies. For all the tests, a P-
value \.05 was considered statistically significant.
Statistical analyses were performed with SPSS for
Windows 11.01 version (SPSS Inc., Chicago, Il, USA).RESULTS
Patient and Graft Characteristics
There were 69 patients (39 men, 30 women) with
a median age of 32 years (range: 2-62 years). The me-
dian follow up was 28 months (range: 0-37 months).
Patient characteristics are summarized in Table 1.
The median stem cell dose infused was 10.3  106
CD34/kg (range: 2.9-61.9).
Engraftment
Sixty-eight (99%) of 69 patients achieved ANC
.0.5  109/L with a median time of 13 days (range:
9-18 days). Sixty-five (94%) patients achieved platelet
count .20  109/l. with a median time of 12 days
(range: 9-160 days). None of the cellular subsets either
in the graft or those reconstituted posttransplant had
an impact on the time to neutrophil and platelet
engraftment.
Relapse
Twenty-one of 69 patients relapsed with a Kaplan-
Meier cumulative relapse incidence of 44% 6 14% at
a median follow up of 28 months. Chimerism analysis
Table 2. Multivariate Relative Risk Analysis for Relapse
Variable RR (95% CI) P Value
Patient age 1.0 (0.95-1.06) .837
Female-to-male transplant 0.5 (0.09-2.39) .351
Myeloablative conditioning 3.7 (0.68-20.04) .130
MNC/kg 1.0 (0.82-1.27) .825
Graft PC ($2.3  106/kg) 3.5 (1.03-12.04) .044
Day 28 CD4 1.0 (1.00-1.00) .957
Day 28-MC low <4.6/mL 3.0 (0.66-13.82) .155
MC indicates monocytoid dendritic cell; MNC, mononuclear cell; PC,
plasmacytoid dendritic cell; RR, relative risk; CI, confidence interval.
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a complete chimera in 91% of (61/67 cases). In 6 cases
(9%) a mixed chimerism pattern was documented at
this time point (with a median donor band of 70.7%
(range: 57-90). Two patients died before day 30, prior
to chimerism analysis. Patients with mixed chimerism
at this time point showed a trend toward an increased
risk of relapse (hazard ratio [HR] 5 3.4, 95%
confidence interval [CI] 1.0-11.7), P 5 .054].Table 3. Comparison of Low and High PC Groups Based on Media
Characteristics
Low Graft PC
(<2.3  106/kg) (n 5 34)
n (%) / median (range)
Patient males 17 (49)
Age (years) 34 (3-54)
Female to male transplant 7 (20)
High risk 20 (57)
Myeloablative conditioning 17 (49)
MNC  108/kg 6.3 (2.7-19)
High risk disease 25 (74)
Graft (106/kg) —
CD34 15.7 (2.9-44.4)
CD3 182.7 (43.4-546.7)
CD19 10.5 (1.5-293.1)
CD4 99.9 (17.9-410.2)
CD4CD45RA 30.8 (1.7-238.9)
CD4CD45RO 43.6 (8-196.3)
CD8 80.2 (15.6-354.5)
CD8CD45RA 48.4 (10.3-175.3)
CD8CD45RO 26.6 (9.9-189.5)
CD16+CD56+CD32 18.6 (2.2-88.5)
ANC >500/mm3 (days) 12 (9-18)
Platelet >20,000 /mm3 (days) 12 (9-38)
Day-28 subsets (106/Lt) —
CD3 720.4 (57.2-3357.5)
CD19 20.8 (1.8-302)
CD4 329.3 ( 23.9-885.6)
CD4CD45RA 82 (9.4-472.2)
CD4CD45RO 167.6 (9.4-580.3)
CD8 306.3 (48-1663.1)
CD8CD45RA 132.4 (18.4-833.5)
CD8CD45RO 114.3 (6.9-1380.7)
CD16+CD56+CD32 234.9 (20.7-620.9)
MC 4.5 (0.3-22.1)
PC 6 (0.3-20)
Acute GVHD (grade 2–4) 10 (29)
Chronic GVHD 18 (62)
Extensive 8 (23.5)
Relapse within 150 days 2 (6)
Death 11 (31)
MC indicates monocytoid dendritic celll; PC, plasmacytoid dendritic cell; GVHThe other factors that were significant in univariate
analysis for an increased incidence of relapse were
patient age, conditioning regimen, plasmacytoid DC
content in the graft, day 28 helper T cells, and PC
counts. On a multivariate analysis (Table 2) after ad-
justing for additional conventional risk factors (such
as female-to-male transplant and cell dose), the only in-
dependent factor associated with higher relapse rate
was high PC content in the graft (HR 5 3.5, 95% CI
1.03-12.0, P 5 0.044). Based on the median value of
PC cell dose, patients were grouped as high ($2.3 
106/kg, n5 35) and low (\2.3  106/kg, n5 34) graft
PC. A comparison of low and high PC groups based on
PC counts in the graft is shown in Table 3. These
2 groups were comparable with regard to recipient
age, sex mismatch transplants, high risk transplants,
graft characteristics (CD34, CD3, CD4, CD8 CD19,
and NK cell dose) and engraftment kinetics of various
cellular subsets (Table 3). In the group of patients
who received a high PC cell dose the cumulative
incidence of relapse was significantly higher than thosen PC in the Graft
High Graft PC
($2.3  106/kg) (n 5 35) P Value
22 (65) .227
28 (2-62) .322
7 (21) 1.000
18 (53) .811
20 (59) .472
6.2 (2-16.3) .936
21 (60) .395
— —
16.9 (5.1-61.9) .760
168.3 (48.1-422.6) .666
12.9 (1.6-54.6) .614
94.1 (31.5-238.2) .755
39.1 (4.7-124.1) .269
47.8 (12.2-168.4) .349
71.7 (22.3-180.7) .408
39.9 (12.7-141.2) .540
20 (5.2-91.1) .195
19.4 (4.7-90) .368
13 (9-17) .116
12 (9-160) .595
— —
816.5 (142.2-15,116.3) .282
37 (2.7-327.9) .133
363.6 (68.4-1926.1) .371
127.2 (6.3-904.2) .111
180.8 (20.6-872.1) .295
342.1 (75.7-13,226.8) .363
166 (28.3-1774) .225
137.4 (11.3-6308.9) .565
220 (51.7-542.1) .682
7.9 (0.4-151.8) .117
7.4 (0.4-72.6) .068
13 (38) .395
16 (59) .390
8 (23) .746
10 (29) .012
19 (56) .053
D, graft-versus-host disease; ANC, absolute neutrophil count.
Figure 1. Cumulative incidence of relapse by graft PC content above
and below the median value of 2.3  106/kg.
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74 6 8% versus 45 6 12% (P 5 .026) (Figure 1). The
relapse risk was significantly more pronounced in the
first 150 days posttransplant in the high PC group.
On subanalysis of patientswhohad anMAversus anon-
myeloablative transplant, the PC dendritic cell content
in the graft as a continuous variable was associated with
an increased relative risk for relapse in both groups,
which was statistically significant only in the MA
group.However, as shown inTable 2 even after adjust-
ing for the conditioning regimen the PC denritic cell
content in the graft above the median value retained
its statistically significant association.Survival
Currently, 39 of 69 patients (57%) are alive at
a median follow up of 2.3 years. Ten of 69 patients
(15%) died of treatment-related mortality within day
100 after transplantation. The Kaplan-Meier estimate
of EFS (relapse or death) at 2 years was 46% 6 6%.
The major causes of death were relapse (n 5 10,
33%), GVHD (n 5 10, 33%), infection (n 5 7,
23%), and regimen-related toxicity (n 5 3, 10%).
High ($2.3  106/kg) PC cell dose remained as
a risk factor for overall (HR 5 2.1, 95% CI 1.0-4.46,
P 5 0.049) and EFS (HR 5 2.5, 95% CI 1.3-4.9,
P 5 0.009), respectively. On a univariate analysis
factors that were significantly associated with OS
were MNC cell dose and PC cell dose, whereas for
EFS significant factors were PC dose in the graft and
day 28 CD4 (both naı¨ve and memory) and the day 28
NK cell count in the recipient. These variables were
all included in multivariate analysis together with stan-
dard risk factors (such as recipient age, female-to-male
transplant, and conditioning regimen). Only a high
($2.3  106/kg) PC cell dose retained statisticalsignificance for reduced EFS (HR 5 3.4, 95% CI
1.4-8.1, P 5 .006) and OS (HR 5 3.1, 95% CI 1.3-
7.9, P 5 .015). Survival curve analysis by a log-rank
test revealed that the group with a high PC cell content
in the graft had a significantly lower EFS (P 5 .007)
and OS (P 5 .044) after PBSCT (Figure 2A and B).
To further validate these observations the cohort was
divided into quartiles based on the PC DC content
in the graft and the impact on the EFS analyzed.
Even when analyzed as quartiles the log-rank test on
the Kaplan-Meier survival EFS curves was significant
(P 5 .045, Figure 2C).Immune Reconstitution post-PBSCT
We prospectively evaluated the impact of post-
transplant reconstitution of cellular subsets on clinical
outcomes such as GVHD, relapse, EFS, andOS in this
cohort of patients. DCs, both monocytoid and plasma-
cytoid, recovered by day 30 posttransplant in this co-
hort (data not shown). We have previously reported
that an early low PCDC count (day 28) as a strong pre-
dictor for development of GVHD in recipients of an
allogeneic matched related PBSCT [12]. In this cohort
also, the median absolute day 28 PC DC counts in pa-
tients with aGVHD grade (II-IV) and cGVHD was
significantly lower compared to those who did not de-
velopGVHD (1.7 versus 7.3 cells/mL, P5 .000 and 2.5
versus 10.3 cell/mL, P 5 .007, respectively). However,
neither the graft MC or PC DC count correlated with
the incidence of aGVHD or cGVHD in this cohort.
None of the reconstituting cellular subsets including
the DCs analyzed at various time points post-
PBSCT had an impact on outcomes such as relapse,
EFS, and OS.DISCUSSION
DC counts in the graft and those engrafted early
posttransplant would have an important impact on
PBSCT outcomes, given the central role for DCs in
the immune response [18,19]. DCs process and
present both endogenously and exogenously derived
antigens. Therefore, in the setting of a HLA
matched allogeneic SCT, DCs arising from the
donor graft and DCs persisting from recipients are
expected to present endogenous minor donor antigen
peptides that will influence T cell activation and/or
induction of tolerance [20]. Recently, Young et al.
[18] have shown the central role of host DCs in recip-
ient antigen presentation to donor T cells, which could
potentially induceGVHD. Recipient DCs are radiore-
sistant and can survive pretransplant conditioning reg-
imens that target cycling or proliferating cells.
Persistent host DCs can function as initiators, as well
as be targets of GVHD reactivity against minor
Figure 2. Kaplan-Meier estimates of (A) EFS and (B) OS by graft PC content above and below the median value of 2.3  106/kg. (C) EFS of the cohort
divided into quartiles by the graft PC content.
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sidual host and engrafting donor APCs contribute to
development of GVHD [18].
A large body of work has addressed the issue of
recipient DC function in initiating and sustaining
GVHD. However, there is limited data on the impact
on graft content of DCs on clinical outcomes. Our data
shows that patients who received high PC cell content
in the graft had a higher incidence of relapse and poor
survival after PBSCT. The role for donor DCs and
their content in the graft has been neglected, in part,
because of their scarcity in grafts, assumptions of lim-
ited survival in allogeneic recipients after transplanta-
tion, and the overwhelming larger numbers of host
DCs that are capable of directly presenting alloantigen
to donor T cells [13]. Recently, Taylor et al. [15] have
shown an important effect of donor APCs, contained
in the graft, in activating host immunity and effector
T cells that mediate graft rejection.
In this analysis patients who received a high PC cell
dose had a higher incidence of relapses, with difference
in early relapses being prominent. This potentially
could be because of a high PC DC content in the graft
shifting the developing donor immune system toward
a type 2 response characterized by decreased Th1cellular immune responses and a decreased graft-
versus-leukemia (GVL) effect [9]. It is also possible
that donor DCs may capture allo-antigen and induce
tolerance to minor histocompatibility antigens in do-
nor T cells (indirect antigen presentation or ‘‘cross-
priming’’), thereby inhibiting the GVL effect [21].
These data are also consistent with a previous report
that suggested that donor DC (similar to a PC immu-
nophenotype) content in the BM graft had an impact
on relapse after BM transplantation [14]. More re-
cently, in vitro analysis has suggested that priming of
naı¨ve andmemory T cells byMC and PCDCs resulted
in divergent T cell responses. MC priming resulted in
significant T cell proliferation and effective priming
of naı¨ve T cells to respond to alloantigen, whereas PC
priming-induced minimal T cell proliferation and
primed T cells remained unresponsive even when
challenged with third-party alloantigens. In addition,
PC priming resulted in induction of regulatory T cell
proliferation [22]. These observed in vitro effects could
also explain our observation of a decreased GVL effect
when the donor PC content in the graft was high result-
ing in an increased risk of relapse. However, we could
not find any association with the graft content of MC
or PC DCs and GVHD. Nor could we demonstrate
860 Biol Blood Marrow Transplant 16:854-860, 2010R. Rajasekar et al.in this cohort an association with reconstitution pat-
terns of regulatory T cells and DC dose in the graft.
In summary, we have shown that PCDC content in
the graft is an independent prognosticator of clinical
outcomes such as relapse and survival in patients
with hematologic malignancies undergoing PBSCT.
Enumerating absolute plasmacytoid dendritic cell count
as reported in our study may be a simple, fast, and
reproducible method to predict clinical outcomes after
PBSCT. PC content in the graft could also potentially
be manipulated to reduce the risk of relapse. It is of
interest that CD123 (interleukin 3 receptor a-chain)
expressed on PC is also an antigenic marker that has
been used to identify leukemic stem cells (LSC) and
differentiate them fromnormalhematopoietic stemcells
[23]. Antibodies directed against CD123 are available
and under evaluation for targeting the LSC [24,25].
Hypothetically, a lytic/toxin bearing antibody directed
against CD123, added to the graft could potentially
reduce the PC content, and subsequent infusion of the
graft with the anti-CD123 antibody would then also
act on any residual LSC in the recipient. The impact
of such a manipulation on immune reconstitution and
GVHD will need to be considered.
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